Currently, there are 98.63M common shares owned by the public and among those 86.10M shares have been available to trade.
Insiders at the company have transacted a total of 11 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 3 of these insider trades were purchases, accounting for 443,844 shares. Insider sales of the common stock occurred on 8 occasions, with total insider shares sold totaling 44,741 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 8.62, up 7.34%. The company’s stock has a 5-day price change of 5.67% and 216.10% over the past three months. FATE shares are trading 99.47% year to date (YTD), with the 12-month market performance up to 28.84% higher. It has a 12-month low price of $1.63 and touched a high of $7.74 over the same period. FATE has an average intraday trading volume of 2.56 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.89%, 50.49%, and 98.13% respectively.
Institutional ownership of Fate Therapeutics Inc (NASDAQ: FATE) shares accounts for 104.56% of the company’s 98.63M shares outstanding.
It has a market capitalization of $735.56M and a beta (3y monthly) value of 1.66. The earnings-per-share (ttm) stands at -$1.63. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.49% over the week and 12.61% over the month.
Analysts forecast that Fate Therapeutics Inc (FATE) will achieve an EPS of -$0.52 for the current quarter, -$0.51 for the next quarter and -$1.66 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.67 while analysts give the company a high EPS estimate of -$0.33. Comparatively, EPS for the current quarter was -$0.19 a year ago. Earnings per share for the fiscal year are expected to decrease by -18.75%, and 8.36% over the next financial year.
Looking at the support for the FATE, a number of firms have released research notes about the stock. Wells Fargo stated their Equal Weight rating for the stock in a research note on March 27, 2023, with the firm’s price target at $6. H.C. Wainwright coverage for the Fate Therapeutics Inc (FATE) stock in a research note released on January 24, 2023 offered a Neutral rating with a price target of $7. Wedbush was of a view on January 06, 2023 that the stock is Neutral, while Truist gave the stock Hold rating on January 06, 2023, issuing a price target of $46- $7. Stifel on their part issued Hold rating on January 06, 2023.
